There are two types of treatment for invasive lung adenocarcinoma. If the lesion is relatively limited, confined to one lobe of the lung, with no metastasis elsewhere, surgical resection can be considered. If the patient’s lesion has spread and is at an intermediate to advanced stage, the pathology done can be genetically tested to further clarify whether the patient is sensitive to targeted drugs and chemotherapy drugs. If the patient is sensitive to both targeted drugs and chemotherapeutic drugs, but the patient is old, over 75 years old, oral targeted drugs are recommended as first-line treatment. If the patient is still physically fit and is a middle-aged male or female aged 50-60, chemotherapy can be chosen as the first line and targeted drugs as the second line, which is the premise that the patient is sensitive to both genetic monitoring and chemotherapy drugs. If the patient is not sensitive to targeted drugs, only chemotherapy is an option. If the patient is not sensitive to chemotherapy regimens and not sensitive to targeted drugs, there is a targeted drug called Anrotinib that can be used, which does not require genetic testing.